This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shepherd, J. Search for Related Content Social Bookmarking                         What's this?

Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification

Department of Vascular Biochemistry, Division of Cardiovascular and Medical Sciences, Macewen Building, Glasgow Royal Infirmary, North Glasgow University Hospital Division, 8 Alexandra Parade, Glasgow, G31 2ER, UK, sbrownlie{at}clinmed.gla.ac.uk

Reduction of low-density lipoprotein cholesterol (LDL-C) is central to the management of cardiovascular risk associated with dyslipidaemia. Yet, at best, this strategy is only capable of a reduction of about 50% in ischaemic vascular disease. Therefore, there is still a need for interventive strategies to improve the situation. Triglyceride lowering and high-density lipoprotein cholesterol (HDL-C) elevation feature prominently in this context, a viewpoint increasingly adopted by international treatment guidelines. This article reviews current thinking on the subject and offers additional treatment strategies for the dyslipidaemic patient.

Key Words: low and high-density lipoproteins • apolipoprotein B • apolipoprotein AI • fibrates • statins • nicotinic acid.

References

• LaRosa JC, He J., Vupputuri S. Effects of statins on risk of coronary disease. A meta-analysis of randomised, controlled studies. JAMA 1999; 282:2340-6.[Abstract/Free Full Text]
• Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486-97.[Free Full Text]
• De backer G., Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.[Free Full Text]
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised, placebo-controlled trial. Lancet 2002;360:7-22.
• Franceschini G., Sirtori CR, Capurso A. et al. A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900.[Web of Science][Medline] [Order article via Infotrieve]
• Weisgraber KH, Rall SC, Bersot TP et al. Apolipoprotein A.- I. Milano. Detection of normal A-I in affected subjects and evidence for a cystine for arginine substitution in the variant A-I. J Biol Chem 1983;258: 2508-13.[Free Full Text]
• Gualandri V., Franceschini G., Sirtori CR et al. A-I Milano Apoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985;37:1083-97.[Web of Science][Medline] [Order article via Infotrieve]
• Franceschini G., Sirtori CR, Bosisio E. et al. Relationship of the phenotypic expression of the A-I Milano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis 1985;58:159-74.[CrossRef][Medline] [Order article via Infotrieve]
• Franceschini G., Calabresi L., Chiesa G. et al. Increased cholesterol efflux potential of sera from apo A-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999;19:1257-62.[Abstract/Free Full Text]
• Ameli S., Hultgardh-Nilsson A., Cercek B. et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994;90:1935-41.[Abstract/Free Full Text]
• Fruchart JC, Staels B., Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83-92.[Medline] [Order article via Infotrieve]
• Frick MH, Elo O., Haapa K. et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia. N Engl J Med 1987;317:1237-45.[Abstract]
• The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-7.[Abstract/Free Full Text]
• Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
• Manninen V., Elo O., Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-55.[Abstract/Free Full Text]
• Yuan J., Tsai MY, Hunninghake DB Change in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Robins SJ, Collins D., Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomised controlled trial. JAMA 2001;285:1585-91.[Abstract/Free Full Text]
• McKenney JM, Proctor JD, Harris S., Chinchili VM A comparison of the efficacy and toxic effects of sustained versus immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.[Abstract/Free Full Text]
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.[Abstract/Free Full Text]
• Canner PL, Berge K., Wenger NK et al. Fifteen year mortality in Coronary drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.[Abstract]
• Brown BG, Zhoo X-Q., Chart A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary dis
• Bays HE, Dujovne CA, McGovern M. et al. Comparison of once daily niacin extended release/lovastatin with standard doses of atorvastatin and simvastatin (ADVOCATE). Am J Cardiol 2003;91:667-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 1 suppl, S12-S16 (2005)
DOI: 10.1177/14746514050050010401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shepherd, J. Search for Related Content Social Bookmarking                         What's this?